Advertisement

European Journal of Nuclear Medicine

, Volume 24, Issue 2, pp 184–191 | Cite as

Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes (“chimney sign”) in occult metastatic medullary thyroid cancer: A typical site of tumour manifestation?

  • Thomas M. Behr
  • Stefan Gratz
  • Peter M. Markus
  • Robert M. Dunn
  • Michael Hüfner
  • Heinz Becker
  • Wolfgang Becker
Original Article

Abstract

In medullary thyroid cancer (MTC), post-surgically elevated plasma calcitonin and/or carcinoembryonic antigen levels frequently indicate persisting metastatic disease, although conventional diagnostic procedures fail to localize the responsible lesions (occult disease). Somatostatin analogues have been used successfully in disease localization, but recently concerns have been raised that increased thoracic uptake of indium-111 pentetreotide in patients with previous external beam irradiation may represent a false-positive finding, caused by post-irradiation pulmonary fibrosis. We recently examined seven patients with metastatic MTC by somatostatin receptor scintigraphy (six with occult and one with established disease). In four patients, all of whom had stable or slowly rising tumour marker levels over several years, a chimney-like bilateral mediastinal uptake of indium-111 penetreotide was found. In two patients with persisting hypercalcitonaemia immediately after primary surgery, supraclavicular lymph node metastases were identified as the responsible lesions. None of these seven patients had prior external beam radiation therapy. In two cases, histological confirmation was obtained. In one patient, disease progression could be shown during follow-up. These data suggest that bilateral mediastinal lymph node involvement is a typical site of disease in slowly progressing occult metastatic MTC; the “chimney sign” may represent a typical finding with somatostatin analogues in such cases. Therefore, we believe that even in the case of prior external beam irradiation, mediastinal uptake of octreotide might represent metastatic MTC rather than radiation fibrosis.

Key words

Medullary thyroid cancer Somatostatin receptor scintigraphy Indium-111 pentetreotide Occult metastatic disease Mediastinal lymph node metastases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Becker W, Spiegel W, Reiners C, Börner W. Besonderheiten bei der Nachsorge des C-Zell-Karzinoms.Der Nuklearmediziner 1986; 9: 167–181.Google Scholar
  2. 2.
    Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid cancer.J Clin Endocrinol Metab 1994; 78: 826–829.PubMedCrossRefGoogle Scholar
  3. 3.
    Busnardo B, Girelli ME, Simioni N, Nacamulli D, Bosetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma.Cancer 1984; 53: 278–285.PubMedCrossRefGoogle Scholar
  4. 4.
    Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma.Surgery 1986; 99: 60–66.PubMedGoogle Scholar
  5. 5.
    Tisell LE, Dilley WG, Wells SA. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels.Surgery 1996; 119: 34–39.PubMedCrossRefGoogle Scholar
  6. 6.
    Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic diease and the role of radiotherapy.J Clin Endocrinol Metab 1988; 67: 801–808.PubMedCrossRefGoogle Scholar
  7. 7.
    Juweid ME, Sharkey RM, Behr T, Swayne LC, Rubin AD, Hanley D, Markowitz A, Siegel J, Goldenberg DM. Targeting and initial radioimmunotherapy of medullary thyroid cancer with131I-labeled monoclonal antibodies to carcinoembryonic antigen.Cancer Res 1995; 55: 5946–5951.Google Scholar
  8. 8.
    Juweid ME, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn RM, Siegel J, Kamal T, Goldenberg DM. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.J Clin Oncol 1996; 14: 1209–1217.PubMedGoogle Scholar
  9. 9.
    Juweid ME, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn RM, Siegel J, Goldenberg DM. Radioimmunotherapy of medullary thyroid carcinoma with131I-labeled anti-CEA antibodies.J Nucl Med 1996; 37: 875–881.Google Scholar
  10. 10.
    Behr TM, Gratz S, Markus PM, Dunn RM, Hüfner M, Schauer A, Fischer M, Munz DL, Becker H, Becker WS. Anti-CEA antibodies versus somatostatin analogs in detection of metastatic medullary thyroid cancer: are CEA and somatostatin-receptor expression prognostic factors? In: Proceedings of the Sixth Conference of Radioimmunodetection and Radioimmunotherapy of Cancer (Princeton, NJ, USA, October 1996).Cancer 1997; in press.Google Scholar
  11. 11.
    Dörr U, Frank-Raue K, Raue F, Buhr HJ, Hehrmann R, Iser G Bihl H. Localization of recurrences from medullary thyroid carcinoma by somatostatin-receptor-scintigraphy [abstract].Eur J Nucl Med 1993; 20: 843.CrossRefGoogle Scholar
  12. 12.
    Frank-Raue K, Bihl H, Dörr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma.Clin Endocrinol 1995; 42: 31–37.Google Scholar
  13. 13.
    Kwekkeboom DJ, Reubi JC, Lamberts SWJ, Bruining HA, Mulder AH, Oei HY, Krenning EP. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.J Clin Endocrinol Metab 1993; 76: 1413–1417.PubMedCrossRefGoogle Scholar
  14. 14.
    Baudin E, Lumbruso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.J Nucl Med 1996; 37: 912–916.PubMedGoogle Scholar
  15. 15.
    Eising EG, Farahati J, Bier D, Knust EJ, Reiners C. Somatostatinrezeptorszintigraphie bei medullären Schilddrüsenkarzinomen, GEP-Tumoren und Karzinoiden.Nucl Med 1995; 34: 1–7.Google Scholar
  16. 16.
    Stoffel M, Jamar, Donckier J, Hainaut P, Decoster P, Beckers C, Pauwels S. Increased uptake of indium-111 pentetreotide up to 10 years after external thoracic irradiation: report of two cases.Eur J Nucl Med 1996; 23: 723–726.PubMedCrossRefGoogle Scholar
  17. 17.
    Reiners C, Eilles C, Spiegel W, Becker W, Börner W. Immunoscintigraphy in medullary thyroid cancer using an123I- or111In-labelled monoclonal anti-CEA antibody fragment.Nucl Med 1986; 25: 227–231.Google Scholar
  18. 18.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Siegel JA, Goldenberg DM. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of CEA-expressing tumors.Cancer Res 1996; 56: 1805–1816.PubMedGoogle Scholar
  19. 19.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Siegel JA, Goldenberg DM. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies.J Nucl Med 1997: in press.Google Scholar
  20. 20.
    Richter E, Feyerabend T.Normal lymph node topography: CT atlas. Berlin, Heidelberg, New York: Springer, 1991.Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Thomas M. Behr
    • 1
  • Stefan Gratz
    • 1
  • Peter M. Markus
    • 2
  • Robert M. Dunn
    • 3
  • Michael Hüfner
    • 4
  • Heinz Becker
    • 2
  • Wolfgang Becker
    • 1
  1. 1.Department of Nuclear MedicineGeorg-August-University of GöttingenGöttingenGermany
  2. 2.Department of Surgery (General and Endocrine Surgery)Georg-August-University of GöttingenGöttingenGermany
  3. 3.Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyBellevilleUSA
  4. 4.Department of Internal Medicine (Endocrinology)Georg-August-University of GöttingenGöttingenGermany

Personalised recommendations